Know Cancer

or
forgot password

Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension


N/A
18 Years
65 Years
Not Enrolling
Both
Muscle Weakness, Pulmonary Arterial Hypertension

Thank you

Trial Information

Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension


Inclusion Criteria:



- Patients with pulmonary arterial hypertension with New York Heart Association stage
II - III disease will be eligible for recruitment in the patient portion of the
trial. Interested healthy age matched volunteers will also be recruited.

Exclusion Criteria:

- Patients and volunteers will be excluded if they have significant co-morbidities
including other cardiorespiratory disease, metabolic abnormalities including diabetes
or thyroid disorders. They will be excluded if they cannot safely exercise and
perform a six minute walk test or if they are wheelchair bound.

Type of Study:

Observational

Study Design:

Observational Model: Cohort

Outcome Measure:

Plasma growth and differentiation factor 15 levels in participants with and without muscle wasting

Outcome Description:

Muscle wasting will be defined by quadriceps cross sectional area measured by ultrasound

Outcome Time Frame:

30 months

Safety Issue:

No

Principal Investigator

Stephen J Wort, MBBS

Investigator Role:

Principal Investigator

Investigator Affiliation:

Imperial College / Royal Brompton Hospital

Authority:

United Kingdom: National Institute for Health Research

Study ID:

13IC0457

NCT ID:

NCT01847716

Start Date:

May 2013

Completion Date:

November 2015

Related Keywords:

  • Muscle Weakness
  • Pulmonary Arterial Hypertension
  • Muscle weakness
  • Pulmonary arterial hypertension
  • Transforming growth factor beta
  • Growth and differentiation factor 15
  • Asthenia
  • Hypertension, Pulmonary
  • Hypertension
  • Muscle Weakness
  • Paresis

Name

Location